Gongwin Biopharm Holdings Co., Ltd. (TPEX:6617)
Taiwan
· Delayed Price · Currency is TWD 75.40
-1.90 (-2.46%)
Apr 29, 2026, 1:30 PM CST
Gongwin Biopharm Holdings Revenue
In the year 2025, Gongwin Biopharm Holdings had annual revenue of 36.45M TWD with 13.75% growth. Gongwin Biopharm Holdings had revenue of 7.91M in the quarter ending December 31, 2025, a decrease of -11.40%.
Revenue
36.45M
Revenue Growth
+13.75%
P/S Ratio
260.07
Revenue / Employee
n/a
Employees
n/a
Market Cap
9.48B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 36.45M | 4.41M | 13.75% |
| Dec 31, 2024 | 32.04M | 13.13M | 69.39% |
| Dec 31, 2023 | 18.92M | 17.77M | 1,554.86% |
| Dec 31, 2022 | 1.14M | - | - |
| Dec 31, 2021 | 1.14M | 310.00K | 37.21% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tanvex BioPharma | 400.97M |
| Ever Supreme Bio Technology | 1.02B |
| PharmaEngine | 911.42M |
| CHO Pharma | 1.43M |
| Adimmune | 1.40B |
| Acepodia | 185.00K |
| TaiGen Biopharmaceuticals Holdings | 259.47M |
| TaiMed Biologics | 611.35M |